Table 1 Biosimilars of ranibizumab
Name of Biosimilar | Manufacturer | Status |
|---|---|---|
Razumab | Intas Pharmaceuticals Ltd., India | Approved by DGCI in 2015 |
Ranizurel/ R-TPR-024 | Reliance Life Sciences, India | Approved by DGCI in 2020 |
SB11 Byooviz | Samsung Bioepis, South Korea | US FDA (2021), EMA (2021) |
FYB201 | Formycon AG/ Bioeq | BLA review accepted by FDA |
Xlucane | Xbrane Biopharma, Sweden | Phase 3 trial active |
SJP-0133/GBS-007 | Senju Pharmaceutical, Japan | Phase 3 trial completed; results awaited |
LUBT010 | Lupin Ltd., India | Phase 3 trial active; recruitment completed |
CKD-701 | Chong Kun Dang, South Korea | Phase 3 trial completed |
PF582 | Pfenex, USA | Phase1/2 trial completed; on hold |
BCD100 | BIOCND, South Korea; Qilu Pharmaceuticals, China | Phase 3 clinical trial active; recruiting |